News

Research with Impact-Dr. Carlos Morillo

  • April 13, 2016
  • News

HHS Research has created a series of articles, which shine the spotlight on studies published in 2014 with an HHS Researcher as lead author. Each piece features a study published in a journal with an Impact Factor greater than 10 and provides information about the author and about the research they lead. If their work strikes a cord with you, Tweet us at @HamHealthSc and include hash tag: HHSResearch

Dr. Carlos Morillo,  MD, FRCP(C), FACC is a Principal Investigator for both the Arrhythmia Program and Neglected Diseases Program – Developing Countries and a member of the Population Health Research Institute. Presently, he is a Professor of Medicine – Division of Cardiology, Department of Medicine, Director of the Syncope and Autonomic Dysfunction Unit, and the Program Director of the Cardiac Electrophysiology and Autonomic Physiology Fellowship. His main research interests are related to the development of clinical trials in the area of cardiac arrhythmias, syncope and treatment of Chagas Disease. His research interests include sympathetic microneurography, baroreflex modulation, heart rate and blood pressure variability, linear and non-linear dynamics of biological signals, plethysmography, lower body negative pressure, and tilt table testing. Dr. Morillo has published more than 260 articles in peer-reviewed journals, over 320 abstracts, and 35 book chapters.

Morillo

Publication:

Morillo, C., Connolly, S., Healey, J. (2014). Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment for paroxysmal atrial fibrillation (RAAFT-2): A randomized trial. Journal of American Medical Association, 311(7), 692-700.

Importance of the study: Atrial fibrillation (AF) is the most common rhythm disorder seen in clinical practice. Antiarrhythmic drugs are effective for reducing the recurrence of AF in patients with symptomatic paroxysmal AF. Radiofrequency ablation is an accepted therapy in patients for whom antiarrhythmic drugs have failed; however, its role as a first-line therapy needs further investigation.

Objective: To compare radiofrequency ablation with antiarrhythmic drugs (standard therapy) in treating patients with paroxysmal AF as a first-line therapy.

Conclusions and relevance: Among patients with paroxysmal AF without previous antiarrhythmic drug treatment, radiofrequency ablation compared with antiarrhythmic drugs resulted in a lower rate of recurrent atrial tachyarrhythmias at two years. However, recurrence was frequent in both groups.

.